Back to Stakeholders

Hospitals Independent Academic Research Groups

Mayo Clinic

United States

8 Trials

Multi-campus academic medical center and one of the most recognized healthcare institutions in the world. Mayo Clinic researchers have published evidence reviews on psilocybin-assisted therapy for depression, anxiety, and alcohol use disorder, and have collaborated on ketamine clinical trials — including a biomarker study with the University of Michigan — for treatment-resistant depression.

Quick Facts

Type: Other
HQ: United States
Website: Visit

Sponsored Trials

7

Intravenous Ketamine for Treatment-Resistant Depression (G2K)

Start Date: March 1, 2025
Compounds: Ketamine, Placebo

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

Start Date: December 1, 2023
Compounds: Ketamine, Placebo

Active not recruitingI

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission

Start Date: March 1, 2019
Compounds: Ketamine

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

Start Date: January 6, 2017
Compounds: Ketamine

Ketamine for Depression and Suicide Risk

Start Date: January 9, 2014
Compounds: Ketamine

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Start Date: January 8, 2012
Compounds: Ketamine, Placebo

Ketamine Anesthesia in Electroconvulsive Therapy

Start Date: January 5, 2011
Compounds: Ketamine, Placebo

Collaborated Trials

1

Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression

Start Date: April 1, 2015
Compounds: Ketamine, Placebo